ClinicalTrials.gg
CompletedNCT03534453L-MOCAUpdated Nov 16, 2026Results posted

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

A Phase 3 interventional study of Olaparib 300mg tablets in Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy and Platinum Sensitive, sponsored by AstraZeneca. Completed at 25 sites in 2 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Nov 16, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
225
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.

Enrollment
16th of 69
225 · median 97
Started
2018
with 6 others
Phase 3
16 of 69
2 open now
Registered
33rd of 69
by date
Lead sponsor
21 of 69
AstraZeneca

Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 16th largest by enrollment, is one of 7 that started in 2018, is one of 16 in phase 3, and was the 33rd registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing olaparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, open-label, single arm, multi-centre interventional study to assess the clinical efficacy and safety of olaparib maintenance monotherapy and will be conducted in patients with platinum sensitive relapsed (PSR) high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy

Read the detailed description

Eligible patients will be those with high grade (serous or endometrioid) epithelial ovarian cancer, primary peritoneal and/or fallopian tube cancer.

Patients must have completed 2 previous lines of platinum-based therapy (e.g., containing carboplatin or cisplatin) and platinum sensitive relapsed before entry to the study. Eligible patients must be in complete or partial response according to RECIST 1.1 criteria following the platinum-based chemotherapy prior to enrolment in the study.

BRCA (Breast Cancer Susceptibility genes) and HRR (Homologous Recombination Repair) mutation status should be determined through blood and/or tumour testing when patients are enrolled in this study.

Patients will be assigned olaparib tablets p.o. 300 mg twice daily. They should initiate olaparib treatment within 8 weeks after their last dose of platinum-containing chemotherapy (last dose is the day of the last infusion).

Patients must have clinical and objective radiological tumour assessments according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria at baseline and every 12 weeks relative to date of enrolment, until objective radiological disease progression as determined by the investigator. Patients could continue to receive olaparib for as long as determined by the investigator, until objective radiological disease progression or as long as in the investigator's opinion they are benefiting from treatment in relation to other clinical assessments and they do not meet any other discontinuation criteria. Once a patient has discontinued olaparib she will be managed as per local clinical practice but will remain in the study and data will be collected on subsequent treatments, progression, overall survival and safety.

03

Conditions studied

  • Relapsed Ovarian Cancer
  • Following Complete or Partial Response to Platinum Based Chemotherapy
  • Platinum Sensitive

Browse trials for

Keywords

  • ovarian cancer
  • PARP Inhibitor
  • Platinum sensitive
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study specific procedures
  2. Age 18 years or over
  3. Patients with platinum sensitive high grade (serous or endometrioid) epithelial ovarian cancers (including primary peritoneal and/or fallopian tube cancer)

    • Platinum sensitive disease is defined as disease progression ≥6 months after completion of their last dose of platinum based chemotherapy
  4. Patients should have received at least 2 previous lines of platinum containing therapy prior to enrolment:

    • For the last chemotherapy course immediately prior to enrolment on the study, patients must be, in the opinion of the investigator, in response (partial or complete radiological response according to 1.1 criteria) and no evidence of a rising CA-125, following completion of this chemotherapy course.
  5. Have availability of 10 ml blood for germline BRCA testing and tumor sample for sBRCA and HRRm testing: paraffin-embedded archived tumor tissue block (preferred) or, if a block is not possible, it would be better to have qualified 15 5-μm unstained sections.
  6. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:

    • ≥ 10.0 g/dL with no blood transfusions in the past 28 days
    • (ANC) ≥ 1.5 x 109/L
    • count ≥ 100 x 109/L
    • Total ≤ 1.5 x institutional (ULN)
    • (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x institutional upper limit of normal unless liver are present in which case they must be ≤ 5x ULN
    • Patients must have estimated using the Cockcroft-Gault equation of ≥51 mL/min:

    Estimated creatinine clearance =[(140-age [years]) x weight (kg)]/[serum creatinine (mg/dL) x 72] (x F)a

    a: where F=0.85 for females and F=1 for males.

  7. (ECOG) performance status 0-1.
  8. Patients must have a ≥ 16 weeks.
  9. or evidence of non-childbearing status for women of : negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1.

    Postmenopausal is defined as:

    • Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments
    • Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the post menopausal range for women under 50
    • radiation-induced oophorectomy with last menses >1 year ago
    • chemotherapy-induced menopause with >1 year interval since last menses
    • surgical sterilisation (bilateral oophorectomy or hysterectomy)
  10. Patients is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.

Exclusion criteria

Exclusion Criteria:

  1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
  2. Previous enrolment in the present study
  3. Participation in another clinical study with an product during the most recent chemotherapy course
  4. Any previous treatment with PARP inhibitor, including olaparib
  5. Other within the last 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma, or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years. Patients with a history of localised triple negative breast cancer may be eligible, provided they completed their chemotherapy more than three years prior to registration, and that the patient remains free of recurrent or disease
  6. Resting with > 470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome
  7. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment
  8. Concomitant use of known strong inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required prior to starting olaparib is 2 weeks.
  9. Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort ) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
  10. Persistent toxicities (>Common Terminology Criteria for Adverse Event () grade 2) caused by previous cancer therapy, excluding alopecia.
  11. Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS/AML.
  12. Patients with symptomatic uncontrolled . A scan to confirm the absence of brain metastases is not required. The patient can receive a stable dose of before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days.
  13. Major surgery within 2 weeks of starting study treatment, or patients have not recovered from any effects of any major surgery.
  14. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining .
  15. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
  16. Breast feeding women.
  17. patients, e.g., patients who are known to be serologically positive for (HIV).
  18. Patients with a known to olaparib or any of the of the product.
  19. Patients with known active hepatitis (i.e. or C) due to risk of transmitting the infection through blood or other body fluids
  20. Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)
  21. Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and transfusions are acceptable, for timing refer to inclusion criteria no.6)
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    Olaparib 300mg tablets

    Taken orally twice daily

    Drug: Olaparib 300mg tablets

Interventions

  • 300mg Olaparib tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from first dose of olaparib until the date of investigator assessed disease progression according to RECIST 1.1 criteria or death (by any cause in the absence of disease progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to disease progression.

    Time frame: Time from first dose of olaparib until the date of investigator assessed disease progressionaccording to RECIST 1.1 criteria or death, whichever came first,up to 79 months

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as the time from the date of first dose of olaparib until the date of death due to any cause.

    Time frame: From the date of first dose of olaparib until the date of death due to any cause, up to 79 months

  2. Time From First Dose to Second Progression (PFS2)

    Time to second progression is defined as the time from the date of first dose of olaparib to the date of the earliest progression event subsequent to that used for the primary variable PFS or death from any cause.

    Time frame: From the date of first dose of olaparib to the date of the earliest progression event subsequent to that used for the primary variable PFS or death from any cause, whichever came first, up to 79 months

  3. Time to First Subsequent Treatment or Death (TFST)

    Time to first subsequent treatment or death is defined as the time from the date of first dose of olaparib to the first subsequent treatment start date, or death date.

    Time frame: Time from the date of first dose of olaparib to the first subsequent treatment start date, or death date, whichever came first, up to 79 months

  4. Time to Second Subsequent Treatment or Death (TSST)

    Time to second subsequent treatment or death is defined as the time from the date of first dose of olaparib to the earlier of the date of second subsequent treatment start date, or death date.

    Time frame: Time from the date of first dose of olaparib to the earlier of the date of second subsequent treatment start date, or death date, whichever came first, up to 79 months

  5. Time to Study Treatment Discontinuation or Death (TDT)

    TDT is defined as the time from the date of first dose of olaparib to the date of study treatment discontinuation or death from any cause.

    Time frame: From date of first dose of olaparib to the date of study treatment discontinuation or death from any cause, whichever came first, up to 79 months

  6. Progression Free Survival (PFS) of BRCAm Population

    Progression free survival (using investigator assessment) according to modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1) of olaparib tablets maintenance monotherapy in BRCA mutated platinum sensitive relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy

    Time frame: Time from first dose of olaparib until the date of investigator assessed disease progression according to RECIST 1.1 criteria or death from any cause, whichever came first, assessed up to 79 months

07

Results

Posted Nov 16, 2026

Participant flow

The study screened the first participant on 29 May 2018 and the last participant's last visit was completed on 27 Jan 2025. A total of 225 participants were enrolled.

Participant flow — Overall Study
MilestoneOlaparib
Started224
Completed67
Not completed157
Withdrew: Subject decision16
Withdrew: Lost to follow-up28
Withdrew: Death112
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS is defined as the time from first dose of olaparib until the date of investigator assessed disease progression according to RECIST 1.1 criteria or death (by any cause in the absence of disease progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to disease progression.

Time frame:
Time from first dose of olaparib until the date of investigator assessed disease progressionaccording to RECIST 1.1 criteria or death, whichever came first,up to 79 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsOlaparib
Progression Free Survival (PFS)16.2 (12.5 to 18.2)
SecondaryOverall Survival (OS)

Overall survival is defined as the time from the date of first dose of olaparib until the date of death due to any cause.

Time frame:
From the date of first dose of olaparib until the date of death due to any cause, up to 79 months
Reported as:
Median · months
Overall Survival (OS)
monthsOlaparib
Overall Survival (OS)51.0 (42.7 to 56.1)
SecondaryTime From First Dose to Second Progression (PFS2)

Time to second progression is defined as the time from the date of first dose of olaparib to the date of the earliest progression event subsequent to that used for the primary variable PFS or death from any cause.

Time frame:
From the date of first dose of olaparib to the date of the earliest progression event subsequent to that used for the primary variable PFS or death from any cause, whichever came first, up to 79 months
Reported as:
Median · months
Time From First Dose to Second Progression (PFS2)
monthsOlaparib
Time From First Dose to Second Progression (PFS2)29.4 (26.2 to 32.8)
SecondaryTime to First Subsequent Treatment or Death (TFST)

Time to first subsequent treatment or death is defined as the time from the date of first dose of olaparib to the first subsequent treatment start date, or death date.

Time frame:
Time from the date of first dose of olaparib to the first subsequent treatment start date, or death date, whichever came first, up to 79 months
Reported as:
Median · months
Time to First Subsequent Treatment or Death (TFST)
monthsOlaparib
Time to First Subsequent Treatment or Death (TFST)18.3 (16.0 to 20.9)
SecondaryTime to Second Subsequent Treatment or Death (TSST)

Time to second subsequent treatment or death is defined as the time from the date of first dose of olaparib to the earlier of the date of second subsequent treatment start date, or death date.

Time frame:
Time from the date of first dose of olaparib to the earlier of the date of second subsequent treatment start date, or death date, whichever came first, up to 79 months
Reported as:
Median · months
Time to Second Subsequent Treatment or Death (TSST)
monthsOlaparib
Time to Second Subsequent Treatment or Death (TSST)34.0 (30.3 to 41.4)
SecondaryTime to Study Treatment Discontinuation or Death (TDT)

TDT is defined as the time from the date of first dose of olaparib to the date of study treatment discontinuation or death from any cause.

Time frame:
From date of first dose of olaparib to the date of study treatment discontinuation or death from any cause, whichever came first, up to 79 months
Reported as:
Median · months
Time to Study Treatment Discontinuation or Death (TDT)
monthsOlaparib
Time to Study Treatment Discontinuation or Death (TDT)13.7 (9.8 to 15.8)
SecondaryProgression Free Survival (PFS) of BRCAm Population

Progression free survival (using investigator assessment) according to modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1) of olaparib tablets maintenance monotherapy in BRCA mutated platinum sensitive relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy

Time frame:
Time from first dose of olaparib until the date of investigator assessed disease progression according to RECIST 1.1 criteria or death from any cause, whichever came first, assessed up to 79 months
Reported as:
Median · months
Progression Free Survival (PFS) of BRCAm Population
monthsOlaparib
Progression Free Survival (PFS) of BRCAm Population20.1 (16.4 to 26.1)

Adverse events

Collected over Time from informed consent to end of the study, up to 79 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olaparib2/224 (0.9%)61/224 (27.2%)0/224 (0%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventOlaparib
AnaemiaBlood and lymphatic system disorders25/224
MyelosuppressionBlood and lymphatic system disorders7/224
IleusGastrointestinal disorders3/224
Intestinal obstructionGastrointestinal disorders3/224
PneumoniaInfections and infestations3/224
SepsisInfections and infestations3/224
ThrombocytopeniaBlood and lymphatic system disorders2/224
Intestinal fistulaGastrointestinal disorders2/224
Jaundice cholestaticHepatobiliary disorders2/224
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/224

Baseline characteristics

Age, Continuous
Age, Continuous(years)Olaparib
Age(years)55.3 ± 8.42
Sex: Female, Male
Sex: Female, Male(Participants)Olaparib
Sex — Female224
Sex — Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Olaparib
Race — Hispanic or Latino0
Race — Not Hispanic or Latino224
Race — Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Olaparib
Race — American Indian or Alaska Native0
Race — Asian224
Race — Native Hawaiian or Other Pacific Islander0
Race — Black or African American0
Race — White0
Race — More than one race0
Race — Unknown or Not Reported0
BRCA status
BRCA status(participants)Olaparib
BRCA mutation106
BRCA wild type117
BRCA unknown1
08

Study locations

25 sites
  • Research Site
    Beijing, 100142, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Chongqing, 400038, China
  • Research Site
    Hangzhou, 310006, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Hefei, 230031, China
  • Research Site
    Jinan, 250012, China
  • Research Site
    Shanghai, 200011, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200080, China
  • Research Site
    Shenyang, 110016, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Tianjin, 300100, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Wuhan, 430079, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Ampang, 68000, Malaysia
  • Research Site
    Johor Bahru, 81100, Malaysia
  • Research Site
    Kuala Lumpur, 59100, Malaysia
  • Research Site
    Kuching, 93586, Malaysia
  • Research Site
    Putrajaya, 62250, Malaysia
09

References and documents

Publications

  • Li H, Peng Z, Zhu J, Zhao W, Huang Y, An R, Zheng H, Qu P, Wang L, Zhou Q, Wang D, Lou G, Wang J, Wang K, Kong B, Xie X, Yin R, Low J, Rozita AM, Sen LC, Meng YC, Kiong KS, Liu J, Liang Z, Lv W, Zhu Y, Hu W, Sun W, Su J, Wang Q, Zang R, Ma D, Gao Q. Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer. BMC Med. 2024 May 16;22(1):199. doi: 10.1186/s12916-024-03409-9. PubMed 38755585 ↗
  • Gao Q, Zhu J, Zhao W, Huang Y, An R, Zheng H, Qu P, Wang L, Zhou Q, Wang D, Lou G, Wang J, Wang K, Low J, Kong B, Rozita AM, Sen LC, Yin R, Xie X, Liu J, Sun W, Su J, Zhang C, Zang R, Ma D. Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA). Clin Cancer Res. 2022 Jun 1;28(11):2278-2285. doi: 10.1158/1078-0432.CCR-21-3023. PubMed 35131903 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Jan 2025, 79 months.

Results were first posted in Nov 2026, 1 year 9 months after primary completion.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 79 months is above that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2018
First posted
May 23, 2018
StartActual
May 29, 2018
Primary completionActual
Jan 27, 2025
CompletionActual
Jan 27, 2025
Results first posted
Nov 16, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 16, 2026
Enrollment
229→225
Nov 16, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Time from first dosing date of olaparib to date of disease progression or death from any cause (if this occurs before disease progression)Now Progression Free Survival (PFS)Time frame: from first dosing date until objective radiological disease progression by RECIST 1.1, or death from any cause, whichever come first, assessed 45 months. → Time from first dose of olaparib until the date of investigator assessed disease progressionaccording to RECIST 1.1 criteria or death, whichever came first,up to 79 months
Nov 16, 2026
Documents
Secondary outcomes
1 edited, 5 added, 10 removed
What changed in the outcomes
  • ChangedBefore Time from first dosing date of olaparib to date of disease progression or death from any cause (if this occurs before disease progression)Now Progression Free Survival (PFS) of BRCAm PopulationTime frame: from first dosing date until objective radiological disease progression by RECIST 1.1, or death from any cause, whichever come first, assessed 45 months. → Time from first dose of olaparib until the date of investigator assessed disease progression according to RECIST 1.1 criteria or death from any cause, whichever came first, assessed up to 79 months
  • AddedOverall Survival (OS)Time frame: From the date of first dose of olaparib until the date of death due to any cause, up to 79 months
  • AddedTime From First Dose to Second Progression (PFS2)Time frame: From the date of first dose of olaparib to the date of the earliest progression event subsequent to that used for the primary variable PFS or death from any cause, whichever came first, up to 79 months
  • AddedTime to First Subsequent Treatment or Death (TFST)Time frame: Time from the date of first dose of olaparib to the first subsequent treatment start date, or death date, whichever came first, up to 79 months
  • AddedTime to Second Subsequent Treatment or Death (TSST)Time frame: Time from the date of first dose of olaparib to the earlier of the date of second subsequent treatment start date, or death date, whichever came first, up to 79 months
  • AddedTime to Study Treatment Discontinuation or Death (TDT)Time frame: From date of first dose of olaparib to the date of study treatment discontinuation or death from any cause, whichever came first, up to 79 months
  • RemovedTime from first dosing date of olaparib to date of death from any causeTime frame: from first dosing date to death, assessed 45 months.
  • RemovedTime from first dosing date of olaparib to date of second progression event or death from any cause (if this occurs before second progression event)Time frame: from first dosing date to second progression, or death from any cause, whichever come first, assessed 45 months.
  • RemovedTime from first dosing date of olaparib to date of first subsequent treatment commencement or death from any cause (if this occurs before commencement of first subsequent treatment)Time frame: Time from first dosing date of olaparib to date of first subsequent treatment commencement or death from any cause (whichever earlier), assessed 45 months.
  • RemovedTime from first dosing date of olaparib to date of second subsequent treatment commencement or death from any cause (if this occurs before commencement of second subsequent treatment)Time frame: Time from first dosing date of olaparib to date of second subsequent treatment commencement or death from any cause (whichever earlier), assessed 45 months.
  • RemovedTime from first dosing date of olaparib to date of olaparib discontinuation or death from any cause (if this occurs before discontinuation of olaparib maintenance therapy)Time frame: Time from first dosing date of olaparib to date of olaparib discontinuation or death from any cause (whichever earlier), assessed 45 months.
  • Removedother outcomeAEs/SAEsTime frame: AEs and SAEs collected from informed consent until post treatment 30-day follow-up period, assessed 45 months.
  • Removedother outcomeclinical chemistry/haematology parameters.Time frame: assessment until post treatment 30-day follow-up period, assessed 45 months.
  • Removedother outcomeImmune-markers PD-L1 expression in tumor tissuesTime frame: PD-L1 expression in tumor tissues before olaparib treatment.
  • Removedother outcomeBRCA mutation status in the cell-free DNA from blood samplesTime frame: at screening (from -28 days to -1 day before baseline)
  • Removedother outcomeother HRR mutation status in the cell-free DNA from blood samplesTime frame: at screening (from -28 days to -1 day before baseline)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Results posted
    Enrollment 229→225
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Time from first dosing date of olaparib to date of disease progression or death from any cause (if this occurs before disease progression)Now Progression Free Survival (PFS)Time frame: from first dosing date until objective radiological disease progression by RECIST 1.1, or death from any cause, whichever come first, assessed 45 months. → Time from first dose of olaparib until the date of investigator assessed disease progressionaccording to RECIST 1.1 criteria or death, whichever came first,up to 79 months
    Secondary outcomes 1 edited, 5 added, 10 removed
    What changed in the outcomes
    • ChangedBefore Time from first dosing date of olaparib to date of disease progression or death from any cause (if this occurs before disease progression)Now Progression Free Survival (PFS) of BRCAm PopulationTime frame: from first dosing date until objective radiological disease progression by RECIST 1.1, or death from any cause, whichever come first, assessed 45 months. → Time from first dose of olaparib until the date of investigator assessed disease progression according to RECIST 1.1 criteria or death from any cause, whichever came first, assessed up to 79 months
    • AddedOverall Survival (OS)Time frame: From the date of first dose of olaparib until the date of death due to any cause, up to 79 months
    • AddedTime From First Dose to Second Progression (PFS2)Time frame: From the date of first dose of olaparib to the date of the earliest progression event subsequent to that used for the primary variable PFS or death from any cause, whichever came first, up to 79 months
    • AddedTime to First Subsequent Treatment or Death (TFST)Time frame: Time from the date of first dose of olaparib to the first subsequent treatment start date, or death date, whichever came first, up to 79 months
    • AddedTime to Second Subsequent Treatment or Death (TSST)Time frame: Time from the date of first dose of olaparib to the earlier of the date of second subsequent treatment start date, or death date, whichever came first, up to 79 months
    • AddedTime to Study Treatment Discontinuation or Death (TDT)Time frame: From date of first dose of olaparib to the date of study treatment discontinuation or death from any cause, whichever came first, up to 79 months
    • RemovedTime from first dosing date of olaparib to date of death from any causeTime frame: from first dosing date to death, assessed 45 months.
    • RemovedTime from first dosing date of olaparib to date of second progression event or death from any cause (if this occurs before second progression event)Time frame: from first dosing date to second progression, or death from any cause, whichever come first, assessed 45 months.
    • RemovedTime from first dosing date of olaparib to date of first subsequent treatment commencement or death from any cause (if this occurs before commencement of first subsequent treatment)Time frame: Time from first dosing date of olaparib to date of first subsequent treatment commencement or death from any cause (whichever earlier), assessed 45 months.
    • RemovedTime from first dosing date of olaparib to date of second subsequent treatment commencement or death from any cause (if this occurs before commencement of second subsequent treatment)Time frame: Time from first dosing date of olaparib to date of second subsequent treatment commencement or death from any cause (whichever earlier), assessed 45 months.
    • RemovedTime from first dosing date of olaparib to date of olaparib discontinuation or death from any cause (if this occurs before discontinuation of olaparib maintenance therapy)Time frame: Time from first dosing date of olaparib to date of olaparib discontinuation or death from any cause (whichever earlier), assessed 45 months.
    • Removedother outcomeAEs/SAEsTime frame: AEs and SAEs collected from informed consent until post treatment 30-day follow-up period, assessed 45 months.
    • Removedother outcomeclinical chemistry/haematology parameters.Time frame: assessment until post treatment 30-day follow-up period, assessed 45 months.
    • Removedother outcomeImmune-markers PD-L1 expression in tumor tissuesTime frame: PD-L1 expression in tumor tissues before olaparib treatment.
    • Removedother outcomeBRCA mutation status in the cell-free DNA from blood samplesTime frame: at screening (from -28 days to -1 day before baseline)
    • Removedother outcomeother HRR mutation status in the cell-free DNA from blood samplesTime frame: at screening (from -28 days to -1 day before baseline)
    + 4 other changes: index terms, verification date, references and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03534453
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 23, 2018
Start date
May 29, 2018
Primary completion
Jan 27, 2025
Completion
Jan 27, 2025
Results posted
Nov 16, 2026
Last update
Nov 16, 2026

Study contacts

Ding MA, PhD
principal investigator · Tongji Hospital, Tongji Medical College of Huazhong University of Sicence and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion